Primecap Management Co. CA Invests $7.14 Million in IQVIA Holdings Inc. $IQV

Primecap Management Co. CA bought a new position in IQVIA Holdings Inc. (NYSE:IQV) during the second quarter, Holdings Channel reports. The fund bought 36,962 shares of the medical research company’s stock, valued at approximately $7,142,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. International Assets Investment Management LLC acquired a new position in shares of IQVIA in the 4th quarter valued at $27,000. Compass Financial Management LLC acquired a new stake in IQVIA during the 2nd quarter worth about $27,000. Gilpin Wealth Management LLC purchased a new stake in IQVIA during the fourth quarter valued at about $27,000. CrossGen Wealth LLC purchased a new stake in IQVIA during the fourth quarter valued at about $28,000. Finally, Activest Wealth Management boosted its holdings in shares of IQVIA by 590.0% in the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after buying an additional 118 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on IQV shares. Weiss Ratings upgraded shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. Barclays reaffirmed an “overweight” rating on shares of IQVIA in a research note on Tuesday, July 28th. Morgan Stanley reiterated an “equal weight” rating and set a $200.00 price objective (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. William Blair raised shares of IQVIA to a “strong-buy” rating in a research note on Tuesday, July 28th. Finally, HSBC reaffirmed a “buy” rating and issued a $240.00 target price on shares of IQVIA in a research report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average target price of $241.88.

Insider Activity at IQVIA

In related news, insider Keriann Cherofsky sold 558 shares of IQVIA stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the completion of the sale, the insider owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. This trade represents a 15.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Bhavik Patel sold 1,855 shares of the business’s stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $235.27, for a total value of $436,425.85. Following the completion of the transaction, the insider owned 1,348 shares in the company, valued at $317,143.96. This trade represents a 57.91% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 12,913 shares of company stock valued at $3,098,793. Insiders own 1.70% of the company’s stock.

IQVIA Price Performance

NYSE IQV opened at $261.57 on Thursday. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. The firm has a market capitalization of $43.05 billion, a price-to-earnings ratio of 32.45, a price-to-earnings-growth ratio of 2.22 and a beta of 1.18. The company has a 50 day simple moving average of $218.41 and a 200-day simple moving average of $188.59. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $262.51.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The firm had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm’s revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the firm posted $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities research analysts predict that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA announced that its Board of Directors has initiated a stock buyback plan on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board of directors believes its shares are undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.